Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Circulated T-cell exhausted subtypes to predict response in PDAC patients.

Anastasia Xagara, Konstantina Vasilieva, Alexandros Kokkalis et al. Jun 01, 2025 pp. 4173-4173 10.1200/jco.2025.43.16_suppl.4173

4173 Background: In-depth analysis of T-cell exhausted subsets in the circulation of Pancreatic Ductal Adenocarcinoma (PDAC) patients may provide insights...

Association of plasma biomarkers with recurrence in glioblastoma.

Miyo K. Chatanaka, Andrew Ajisebutu, Leonardo Macedo Filho et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14017

e14017 Background: Adult-type diffuse gliomas are common malignant tumors known for their high recurrence rates, regardless of grade. High recurrence is d...

Multicenter phase I/II study of abemaciclib and ramucirumab in metastatic gastroesophageal adenocarcinoma (GEA): CDK4/6 and cyclin D1 alterations as a predictor of response and survival.

Ronan Joseph Kelly, Vincent K. Lam, Andrew Scott Paulson et al. Jun 01, 2025 pp. 4063-4063 10.1200/jco.2025.43.16_suppl.4063

4063 Background: CDK4/6 and Cyclin D1 are highly expressed in GEA cancers, suggesting that CDK4/6 inhibition may be a promising strategy. In v...

Gene-specific outcomes in patients with Lynch syndrome treated by immune checkpoint blockade for advanced cancer.

Violaine Randrian, Oliver Artz, Mohammad Abbass et al. Jun 01, 2025 pp. 10504-10504 10.1200/jco.2025.43.16_suppl.10504

10504 Background: Lynch syndrome (LS), caused by germline pathogenic variants (gPVs) in DNA mismatch repair genes ( MLH1, MSH2, MSH6, PMS2...

Clinical characteristics and survival outcomes in ovarian carcinosarcoma compared to serous carcinoma: A population-based analysis.

Hao Zhou, Zhengxiao Yang, Han Liu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17605

e17605 Background: Serous ovarian carcinoma (SOC) is the most common form of ovarian cancer, whereas ovarian carcinosarcoma (OCS) is a much rarer subtype....

TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with <i>EGFR</i> -mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC).

Shun Lu, Mariano Provencio, Aaron Lisberg et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps8647

TPS8647 Background: Despite the benefit observed with osimertinib, most patients with LA/M EGFR -mutated NSCLC develop resistance...

Radiotherapy followed by systemic therapy and tislelizumab in MSS rectal cancer with liver metastases: Using single-cell RNA sequencing to reveal cellular dynamics in primary rectal cancer and paired liver metastases of patients enrolled in the MIRACLE-1 and MIRACLE-2 studies.

Ruone Xu, Menglong Zhou, Lijun Shen et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15521

e15521 Background: Liver metastasis remains a major hurdle to long-term survival of patients with rectal cancer. These patients with metastases could bene...

Neoadjuvant therapy in resectable small-cell lung cancer: A systematic review and meta-analysis.

Wentao Hu, Jian Chen, Lifei Meng et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20101

e20101 Background: Surgery, chemotherapy, and immunotherapy constitute the cornerstone therapeutic regimen for patients with small-cell lung cancer (SCLC)...

Neoadjuvant lazertinib with or without chemotherapy for patients with epidermal growth factor receptor ( <i>EGFR</i> )-mutated resectable non-small cell lung cancer (NSCLC): NeoLazer trial.

Hye Ryun Kim, Se-Hoon Lee, Se Hyun Kim et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps8119

TPS8119 Background: While perioperative systemic treatment with checkpoint inhibitors plus chemotherapy has become a standard approach for resectable NSCL...

Impact of SARS-CoV-2 mRNA-BNT162b2 vaccination on survival outcomes in metastatic colorectal cancer patients treated with bevacizumab-based therapy.

Coskun Yazgan, Beliz Bahar Karaoğlan, Erman Akkus et al. Jun 01, 2025 pp. 3574-3574 10.1200/jco.2025.43.16_suppl.3574

3574 Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Bevacizumab, an anti-vascular endothelial growth factor...

Sintilimab (anti-PD-1) plus ifosfamide, carboplatin, and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind phase 3 study (ORIENT-21).

Peng Liu, Zhiming Li, Hong Cen et al. Jun 01, 2025 pp. 7007-7007 10.1200/jco.2025.43.16_suppl.7007

7007 Background: Sintilimab monotherapy for cHL in third-line setting and beyond has been evaluated in a single-arm, phase 2 study ORIENT-1. Here, we pres...

Meat consumption and colorectal cancer risk: A comprehensive meta-analysis of red, processed, and total meat intake.

Andrea Lehoczki, Otilia Menyhart, Gyöngyi Munkácsy et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22508

e22508 Background: Red and processed meats have long been implicated as dietary risk factors for colorectal cancer (CRC). However, limited attention has b...

Clinical and demographic profiles and predictors of survival in epithelioid trophoblastic tumors: A population-based analysis.

Zhuoran Xiao, Hao Zhou, Zhengxiao Yang et al. Jun 01, 2025 pp. 5615-5615 10.1200/jco.2025.43.16_suppl.5615

5615 Background: Epithelioid trophoblastic tumor (ETT) is a rare form of gestational trophoblastic neoplasia. Existing studies on ETT have been limited by...

Impact of large language models on trial-to-patient matching efficiency.

Nathan T. Rich, Sarah Salzman, Gabriel Altay et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13600

e13600 Background: Timely and accurate clinical trial matching is critical to providing additional treatment options for patients, especially when standar...

Alcohol use and subsequent primary cancer in breast cancer survivors: A case-cohort study.

Asra Shaik, David R Doody, Kathleen Malone et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22562

e22562 Background: With continued advances in treatment, there are an increasing number of breast cancer survivors at risk of developing a second primary...

Genomic profiles in prostate cancer patients of varying measured socioeconomic inequality: A retrospective cohort study.

Rishab Srivastava, Megan Taylor, Kenneth Barker et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17159

e17159 Background: Socioeconomic inequality (SI) is a recognized risk factor for negative outcomes in prostate cancer (PCa), influenced by biology, health...

Hepatotoxic adverse events with immune checkpoint inhibitors: Real world pharmacovigilance study using FAERS database.

Panah Tushar Parab, Nikhil Vojjala, Charmi Bhanushali et al. Jun 01, 2025 pp. 2602-2602 10.1200/jco.2025.43.16_suppl.2602

2602 Background: Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment. With their increasing use, it is important to...

Racial and ethnic disparities in risk of second primary lung cancer among initial lung cancer survivors in the United States.

Pragati Gole Advani, Christina R. Crabtree-Ide, Sarah Mullin et al. Jun 01, 2025 pp. 8037-8037 10.1200/jco.2025.43.16_suppl.8037

8037 Background: Previous studies have reported significant racial/ethnic disparities in incidence and mortality of lung cancer. However, with several stu...

Assessing the safety and efficacy of GT201: A first-in-class autologous tumor-infiltrating lymphocyte monotherapy in advanced solid tumors.

Pin Wang, Jing Yu, Yue He et al. Jun 01, 2025 pp. 6038-6038 10.1200/jco.2025.43.16_suppl.6038

6038 Background: For patients with unresectable recurrent or metastatic solid tumors that progress after chemotherapy, immune checkpoint inhibitors (ICIs)...

Immune checkpoint inhibitors (ICI) in thymic epithelial tumors (TET): A real world assessment of efficacy and toxicity.

Guilherme Sacchi De Camargo Correia, Reema Tawfiq, Yanyan Lou et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20141

e20141 Background: TET are rare and challenging entities in clinical practice. Prospective trials in thymoma and thymic carcinoma (TC) are scarce. Limited...

Family mental illness and physical abuse for predicting cannabis use among cancer survivors.

Oluwole Adeyemi Babatunde, Nosa Osazuwa-Peters, Eric Adjei Boakye Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22616

e22616 Background: Adults with a history of Adverse Childhood Experiences (ACEs) are more likely to engage in health-risk behaviors. While the link betwee...

A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combination with cisplatin for patients with platinum sensitive recurrent ovarian and endometrial cancer.

Melanie Wain Kier, Erin L. Moshier, Stephanie V. Blank et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps5623

TPS5623 Background: Sacituzumab govitecan (SG) is an antibody-drug conjugate (ADC) composed of the irinotecan active metabolite SN-38 (govitecan) covalent...

Efficacy and safety of serplulimab with DP induction chemotherapy followed by nimotuzumab and IMRT in locally advanced nasopharyngeal carcinoma: A retrospective study.

Jiawei Chen, Xiaopeng Huang, Shuai Zhang Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18093

e18093 Background: Induction chemotherapy is the new standard of care for locally advanced nasopharyngeal carcinoma (LANPC). Whereas managing LANPC still...

Serial circulating tumor DNA (ctDNA) monitoring in early-stage, HR+/HER2-, invasive lobular carcinoma (ILC) of the breast and impact on clinical outcomes.

Julia Foldi, Samuel Rivero-Hinojosa, Sandro Satta et al. Jun 01, 2025 pp. 581-581 10.1200/jco.2025.43.16_suppl.581

581 Background: ILC accounts for ~10-15% of breast cancer (BC) cases in the US with difficult-to-diagnose patterns of metastasis. Loss of E-cadherin (...

Outcomes of immunotherapy in advanced osteosarcoma patients: A systematic review and meta-analysis.

Iqra Anwar, Hafiz Muhammad Hannan Javed, Muhammad Fareed Khalid et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23515

e23515 Background: Osteosarcoma is the most commonly diagnosed primary bone tumor. Advanced or metastatic osteosarcoma is a very aggressive tumor with poo...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page